Dibenzepin as an antifibrillatory agent for spontaneously terminating electrically induced ventricular fibrillation.
The effect of dibenzepin, a tricyclic antidepressant drug, on electrically induced ventricular fibrillation was studied in 20 cats and nine dogs. The ventricular fibrillation threshold and the ability of the ventricle to defibrillate spontaneously were determined before and after the administration of dibenzepin, with each animal serving as its own control. The drug raised the ventricular fibrillation threshold in all the animals tested. Before treatment, spontaneous ventricular defibrillation occurred in only 8 of the 20 cats and in none of the dogs. After treatment, all of the cats and eight of the dogs exhibited spontaneous ventricular defibrillation. The study of drugs that have a self-defibrillatory effect may serve to further understanding of the mechanism of ventricular fibrillation and its spontaneous termination.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial; D002415:Cats; D003984:Dibenzazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005260:Female; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D014693:Ventricular Fibrillation / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D000929:Antidepressive Agents, Tricyclic; D003984:Dibenzazepines